AACR 2025 | First-in-human results of ART0380 and irinotecan in solid tumors

Susanna Ulahannan • 2 May 2025

AACR 2025

ART0380-01

Susanna Ulahannan, MD, University of Oklahoma Health Sciences Center, Oklahoma City, OK, discussed first-in-human findings from the ART0380-01 trial (NCT04657068) of the ATR inhibitor ART0380 with low-dose irinotecan in advanced solid tumors. The regimen was well tolerated and showed encouraging antitumor activity, particularly in patients with ATM-deficient tumors. The dual strategy of exploiting replication stress and ATR inhibition produced objective responses and manageable toxicity. These results support further investigation using biomarker-driven selection to refine efficacy in this molecularly defined population. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.